Efficacy and treatment costs of Zoledronate versus Pamidronate in Paediatric Osteoporosis

Vrinda Saraff, Jaskiran Sahota, Nicola Crabtree, Sophia Sakka, Nicholas Shaw, Wolfgang Högler

Research output: Contribution to journalArticlepeer-review

554 Downloads (Pure)


Intravenous pamidronate has been used in the treatment of osteogenesis imperfecta (OI) in children for over 20 years. The more potent zoledronate is an attractive alternative as it is administered less frequently. This study compares the clinical efficacy of intravenous pamidronate (1.5 mg/kg/day over 2 days, every 3 months) versus zoledronate (0.05 mg/kg/dose every 6 months) in 40
children (20 per group) with mild to moderate OI and the treatment costs of the two drugs in a tertiary centre for children with osteoporosis. Lumbar spine bone
mineral density and fracture rate did not differ between drug groups following 1 and 2 years of treatment, respectively. Total cost per treatment course per patient was £1157 for pamidronate and £498 for zoledronate.
Therefore, zoledronate is a considerably cheaper alternative to pamidronate with comparable efficacy, resulting in substantial annual savings for healthcare
providers and a more convenient option for patients due to fewer hospital visits.
Original languageEnglish
JournalArchives of Disease in Childhood
Early online date7 Oct 2017
Publication statusE-pub ahead of print - 7 Oct 2017


Dive into the research topics of 'Efficacy and treatment costs of Zoledronate versus Pamidronate in Paediatric Osteoporosis'. Together they form a unique fingerprint.

Cite this